Advertisement

Exploring Protein-Ligand and Protein-Protein Interactions

  • Tim Skern
Chapter
Part of the Learning Materials in Biosciences book series (LMB)

Abstract

In this chapter, we will explore how two intracellular proteins bind their respective ligands and observe the ensuing conformational changes. The first protein is p21ras, a molecule that binds guanosine diphosphate (GDP) in the ground state and guanosine triphosphate (GTP) in the activated state. It is of therapeutic interest because activation can be brought about by the hormone insulin; in addition, p21ras is often mutated in human cancers. The second protein is eukaryotic initiation factor (eIF) 4E, a protein that recognizes the 7-methyl-G(5′)ppp(5′) cap structure on the 5′ end of eukaryotic mRNA molecules. It also responds to insulin stimulation, and there is evidence that it is a proto-oncogene. The ligands they bind are both guanosine nucleotides; however, we will see that the folds of the proteins and their interactions with the ligands differ. We will also observe the consequences of binding or exchanging ligands and visualize how the proteins form complexes with their specific macromolecular interaction partners. These investigations will illustrate basic principles from the previous four chapters and will provide you with the skills and tools required to compare structures by superposition.

References

  1. Aumayr M, Fedosyuk S, Ruzicska K, Sousa-Blin C, Kontaxis G, Skern T (2015) NMR analysis of the interaction of picornaviral proteinases Lb and 2A with their substrate eukaryotic initiation factor 4GII. Protein Sci 24(12):1979–1996.  https://doi.org/10.1002/pro.2807 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Bellsolell L, Cho-Park PF, Poulin F, Sonenberg N, Burley SK (2006) Two structurally atypical HEAT domains in the C-terminal portion of human eIF4G support binding to eIF4A and Mnk1. Structure 14(5):913–923.  https://doi.org/10.1016/j.str.2006.03.012 CrossRefPubMedGoogle Scholar
  3. Campbell R (2016) Introduction to structural alignment with PyMOL. http://pldserver1.biochem.queensu.ca/~rlc/work/teaching/BCHM823/pymol/alignment/. Accessed 27.11 2017
  4. Gruner S, Peter D, Weber R, Wohlbold L, Chung MY, Weichenrieder O, Valkov E, Igreja C, Izaurralde E (2016) The structures of eIF4E-eIF4G complexes reveal an extended interface to regulate translation initiation. Mol Cell 64(3):467–479.  https://doi.org/10.1016/j.molcel.2016.09.020 CrossRefPubMedGoogle Scholar
  5. Jia Y, Polunovsky V, Bitterman PB, Wagner CR (2012) Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target. Med Res Rev 32(4):786–814.  https://doi.org/10.1002/med.21260 CrossRefPubMedGoogle Scholar
  6. Kim SH, Quigley GJ, Suddath FL, McPherson A, Sneden D, Kim JJ, Weinzierl J, Rich A (1973) Three-dimensional structure of yeast phenylalanine transfer RNA: folding of the polynucleotide chain. Science 179(4070):285–288CrossRefPubMedGoogle Scholar
  7. Laskowski RA, Jablonska J, Pravda L, Varekova RS, Thornton JM (2017) PDBsum: structural summaries of PDB entries. Protein Sci.  https://doi.org/10.1002/pro.3289
  8. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK (1997) Cocrystal structure of the messenger RNA 5′ cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell 89(6):951–961CrossRefPubMedGoogle Scholar
  9. Marcotrigiano J, Lomakin IB, Sonenberg N, Pestova TV, Hellen CU, Burley SK (2001) A conserved HEAT domain within eIF4G directs assembly of the translation initiation machinery. Mol Cell 7(1):193–203CrossRefPubMedGoogle Scholar
  10. Merrick WC (2015) eIF4F: a retrospective. J Biol Chem 290(40):24091–24099.  https://doi.org/10.1074/jbc.R115.675280 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Milburn MV, Tong L, deVos AM, Brunger A, Yamaizumi Z, Nishimura S, Kim SH (1990) Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 247(4945):939–945CrossRefGoogle Scholar
  12. Papke B, Der CJ (2017) Drugging RAS: know the enemy. Science 355(6330):1158–1163.  https://doi.org/10.1126/science.aam7622 CrossRefPubMedGoogle Scholar
  13. Peter D, Igreja C, Weber R, Wohlbold L, Weiler C, Ebertsch L, Weichenrieder O, Izaurralde E (2015) Molecular architecture of 4E-BP translational inhibitors bound to eIF4E. Mol Cell 57(6):1074–1087.  https://doi.org/10.1016/j.molcel.2015.01.017 CrossRefPubMedGoogle Scholar
  14. Prior IA, Lewis PD, Mattos C (2012) A comprehensive survey of Ras mutations in cancer. Cancer Res 72(10):2457–2467.  https://doi.org/10.1158/0008-5472.CAN-11-2612 CrossRefPubMedPubMedCentralGoogle Scholar
  15. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, Wittinghofer A (1997) The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277(5324):333–338CrossRefGoogle Scholar
  16. Stephen AG, Esposito D, Bagni RK, McCormick F (2014) Dragging ras back in the ring. Cancer Cell 25(3):272–281.  https://doi.org/10.1016/j.ccr.2014.02.017 CrossRefPubMedGoogle Scholar
  17. Stierand K, Rarey M (2010) Drawing the PDB: protein-ligand complexes in two dimensions. ACS Med Chem Lett 1(9):540–545.  https://doi.org/10.1021/ml100164p CrossRefPubMedPubMedCentralGoogle Scholar
  18. Sussman JL, Holbrook SR, Warrant RW, Church GM, Kim SH (1978) Crystal structure of yeast phenylalanine transfer RNA. I Crystallographic refinement J Mol Biol 123(4):607–630PubMedGoogle Scholar
  19. Tong LA, de Vos AM, Milburn MV, Kim SH (1991) Crystal structures at 2.2 Å resolution of the catalytic domains of normal ras protein and an oncogenic mutant complexed with GDP. J Mol Biol 217(3):503–516CrossRefPubMedGoogle Scholar
  20. Volpon L, Osborne MJ, Topisirovic I, Siddiqui N, Borden KL (2006) Cap-free structure of eIF4E suggests a basis for conformational regulation by its ligands. EMBO J 25(21):5138–5149.  https://doi.org/10.1038/sj.emboj.7601380 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Tim Skern
    • 1
  1. 1.Max F. Perutz LaboratoriesMedical University of ViennaViennaAustria

Personalised recommendations